Fig 1: Association of serum ECP with therapy response and clinically relevant prognostic markers. (A,B) Association of response to targeted therapy with established prognostic markers such as LDH, AEC, REC, ANC and RNC. Comparing depicted clinical blood parameters of responders to non-responders (A) prior to treatment and (B) during drug administration. Responders show significantly higher AEC values prior to administration compared to non-responders. Responders are defined as CR or PR and non-responders as PD at time of assessment. Box plots show levels of clinical markers (median and the 25th and 75th percentiles; whiskers represent minimal and maximal outliers), as well as individual data points. (C) Comparison of serum ECP concentration (ng/mL) of responders and non-responders (left) prior (TT pre) and (right) during (TT on) targeted therapy. There is a trend towards higher pre-therapeutic values of ECP in melanoma patients with disease progression compared to responders. (D) Association of pre-treatment REC with response to MAPKi or PD-1 treatment in an independent patient cohort. In total, 50 patients (CR or PR n = 39; SD or PD n = 11) with metastatic melanoma were included in the MAPKi cohort and 59 patients (CR or PR n = 32; SD or PD n = 27) were included in the PD-1 cohort. High REC was significantly correlated with better response to MAPKi but not to PD-1 monotherapy. Mann–Whitney U test was used to compare REC in responders and non-responders.
Supplier Page from CUSABIO Technology LLC for Human eosinophil cationic protein,ECP ELISA Kit